Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew Berry is active.

Publication


Featured researches published by Andrew Berry.


Cell Metabolism | 2012

Human β Cell Transcriptome Analysis Uncovers lncRNAs That Are Tissue-Specific, Dynamically Regulated, and Abnormally Expressed in Type 2 Diabetes

Ignasi Moran; Ildem Akerman; Martijn van de Bunt; Ruiyu Xie; Marion Benazra; Takao Nammo; Luis Arnes; Nikolina Nakić; Javier García-Hurtado; Santiago A. Rodríguez-Seguí; Lorenzo Pasquali; Claire Sauty-Colace; Anthony Beucher; Raphael Scharfmann; Joris van Arensbergen; Paul Johnson; Andrew Berry; Clarence Lee; Timothy T. Harkins; Valery Gmyr; François Pattou; Julie Kerr-Conte; Lorenzo Piemonti; Thierry Berney; Neil A. Hanley; A L Gloyn; Lori Sussel; Linda Langman; Kenneth L. Brayman; Maike Sander

A significant portion of the genome is transcribed as long noncoding RNAs (lncRNAs), several of which are known to control gene expression. The repertoire and regulation of lncRNAs in disease-relevant tissues, however, has not been systematically explored. We report a comprehensive strand-specific transcriptome map of human pancreatic islets and β cells, and uncover >1100 intergenic and antisense islet-cell lncRNA genes. We find islet lncRNAs that are dynamically regulated and show that they are an integral component of the β cell differentiation and maturation program. We sequenced the mouse islet transcriptome and identify lncRNA orthologs that are regulated like their human counterparts. Depletion of HI-LNC25, a β cell-specific lncRNA, downregulated GLIS3 mRNA, thus exemplifying a gene regulatory function of islet lncRNAs. Finally, selected islet lncRNAs were dysregulated in type 2 diabetes or mapped to genetic loci underlying diabetes susceptibility. These findings reveal a new class of islet-cell genes relevant to β cell programming and diabetes pathophysiology.


Journal of Biological Chemistry | 2004

Glucocorticoid Ligands Specify Different Interactions with NF-κB by Allosteric Effects on the Glucocorticoid Receptor DNA Binding Domain

Helen Garside; Adam Stevens; Stuart N. Farrow; Claire Normand; Benoit Houle; Andrew Berry; Barbara Maschera; David Ray

Glucocorticoids inhibit inflammation by acting through the glucocorticoid receptor (GR) and powerfully repressing NF-κB function. Ligand binding to the C-terminal of GR promotes the nuclear translocation of the receptor and binding to NF-κB through the GR DNA binding domain. We sought how ligand recognition influences the interaction between NF-κB and GR. Both dexamethasone (agonist) and RU486 (antagonist) promote efficient nuclear translocation, and we show occupancy of the same intranuclear compartment as NF-κB with both ligands. However, unlike dexamethasone, RU486 had negligible activity to inhibit NF-κB transactivation. This failure may stem from altered co-factor recruitment or altered interaction with NF-κB. Using both glutathione S-transferase pull-down and bioluminescence resonance energy transfer approaches, we identified a major glucocorticoid ligand effect on interaction between the GR and the p65 component of NF-κB, with RU486 inhibiting recruitment compared with dexamethasone. Using the bioluminescence resonance energy transfer assay, we found that RU486 efficiently recruited NCoR to the GR, unlike dexamethasone, which recruited SRC1. Therefore, RU486 promotes differential protein recruitment to both the C-terminal and DNA binding domain of the receptor. Importantly, using chromatin immunoprecipitation, we show that impaired interaction between GR and p65 with RU486 leads to reduced recruitment of the GR to the NF-κB-responsive region of the interleukin-8 promoter, again in contrast to dexamethasone that significantly increased GR binding. We demonstrate that ligand-induced conformation of the GR C-terminal has profound effects on the functional surface generated by the DNA binding domain of the GR. This has implications for understanding ligand-dependent interdomain communication.


Journal of Hepatology | 2015

Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes

Melissa A. Baxter; Sarah Withey; Sean Harrison; Charis-Patricia Segeritz; Fang Zhang; Rebecca Atkinson-Dell; Cliff Rowe; Dave T. Gerrard; Rowena Sison-Young; Roz Jenkins; Joanne Henry; Andrew Berry; Lisa Mohamet; Marie Best; Stephen W. Fenwick; Hassan Z. Malik; Neil R. Kitteringham; Christopher E. Goldring; Karen Hanley; Ludovic Vallier; Neil A. Hanley

Graphical abstract


Diabetes | 2013

Development of the human pancreas from foregut to endocrine commitment

Rachel Jennings; Andrew Berry; Rebecca Kirkwood-Wilson; Neil A. Roberts; Thomas Hearn; Rachel J. Salisbury; Jennifer Blaylock; Karen Hanley; Neil A. Hanley

Knowledge of human pancreas development underpins our interpretation and exploitation of human pluripotent stem cell (PSC) differentiation toward a β-cell fate. However, almost no information exists on the early events of human pancreatic specification in the distal foregut, bud formation, and early development. Here, we have studied the expression profiles of key lineage-specific markers to understand differentiation and morphogenetic events during human pancreas development. The notochord was adjacent to the dorsal foregut endoderm during the fourth week of development before pancreatic duodenal homeobox-1 detection. In contrast to the published data from mouse embryos, during human pancreas development, we detected only a single-phase of Neurogenin 3 (NEUROG3) expression and endocrine differentiation from approximately 8 weeks, before which Nirenberg and Kim homeobox 2.2 (NKX2.2) was not observed in the pancreatic progenitor cell population. In addition to revealing a number of disparities in timing between human and mouse development, these data, directly assembled from human tissue, allow combinations of transcription factors to define sequential stages and differentiating pancreatic cell types. The data are anticipated to provide a useful reference point for stem cell researchers looking to differentiate human PSCs in vitro toward the pancreatic β-cell so as to model human development or enable drug discovery and potential cell therapy.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Antigenic diversity is generated by distinct evolutionary mechanisms in African trypanosome species

Andrew P. Jackson; Andrew Berry; Martin Aslett; Harriet C. Allison; Peter Burton; Jana Vavrova-Anderson; Robert H. Brown; Hilary P. Browne; Nicola Corton; Heidi Hauser; John Gamble; Ruth Gilderthorp; Lucio Marcello; Jacqueline McQuillan; Thomas D. Otto; Michael A. Quail; Mandy Sanders; Andries J. van Tonder; Michael L. Ginger; Mark C. Field; J. David Barry; Christiane Hertz-Fowler; Matthew Berriman

Antigenic variation enables pathogens to avoid the host immune response by continual switching of surface proteins. The protozoan blood parasite Trypanosoma brucei causes human African trypanosomiasis (“sleeping sickness”) across sub-Saharan Africa and is a model system for antigenic variation, surviving by periodically replacing a monolayer of variant surface glycoproteins (VSG) that covers its cell surface. We compared the genome of Trypanosoma brucei with two closely related parasites Trypanosoma congolense and Trypanosoma vivax, to reveal how the variant antigen repertoire has evolved and how it might affect contemporary antigenic diversity. We reconstruct VSG diversification showing that Trypanosoma congolense uses variant antigens derived from multiple ancestral VSG lineages, whereas in Trypanosoma brucei VSG have recent origins, and ancestral gene lineages have been repeatedly co-opted to novel functions. These historical differences are reflected in fundamental differences between species in the scale and mechanism of recombination. Using phylogenetic incompatibility as a metric for genetic exchange, we show that the frequency of recombination is comparable between Trypanosoma congolense and Trypanosoma brucei but is much lower in Trypanosoma vivax. Furthermore, in showing that the C-terminal domain of Trypanosoma brucei VSG plays a crucial role in facilitating exchange, we reveal substantial species differences in the mechanism of VSG diversification. Our results demonstrate how past VSG evolution indirectly determines the ability of contemporary parasites to generate novel variant antigens through recombination and suggest that the current model for antigenic variation in Trypanosoma brucei is only one means by which these parasites maintain chronic infections.


American Journal of Human Genetics | 2013

Perrault syndrome is caused by recessive mutations in CLPP, encoding a mitochondrial ATP-dependent chambered protease.

Emma M. Jenkinson; Atteeq U. Rehman; Tom Walsh; Jill Clayton-Smith; Kwanghyuk Lee; Robert J. Morell; Meghan C. Drummond; Shaheen N. Khan; Muhammad Asif Naeem; Bushra Rauf; Neil Billington; Julie M. Schultz; Jill Urquhart; Ming K. Lee; Andrew Berry; Neil A. Hanley; Sarju G. Mehta; Deirdre Cilliers; Peter Clayton; Helen Kingston; Miriam J. Smith; Thomas T. Warner; Graeme C.M. Black; Dorothy Trump; Julian R.E. Davis; Wasim Ahmad; Suzanne M. Leal; Sheikh Riazuddin; Mary Claire King; Thomas B. Friedman

Perrault syndrome is a genetically and clinically heterogeneous autosomal-recessive condition characterized by sensorineural hearing loss and ovarian failure. By a combination of linkage analysis, homozygosity mapping, and exome sequencing in three families, we identified mutations in CLPP as the likely cause of this phenotype. In each family, affected individuals were homozygous for a different pathogenic CLPP allele: c.433A>C (p.Thr145Pro), c.440G>C (p.Cys147Ser), or an experimentally demonstrated splice-donor-site mutation, c.270+4A>G. CLPP, a component of a mitochondrial ATP-dependent proteolytic complex, is a highly conserved endopeptidase encoded by CLPP and forms an element of the evolutionarily ancient mitochondrial unfolded-protein response (UPR(mt)) stress signaling pathway. Crystal-structure modeling suggests that both substitutions would alter the structure of the CLPP barrel chamber that captures unfolded proteins and exposes them to proteolysis. Together with the previous identification of mutations in HARS2, encoding mitochondrial histidyl-tRNA synthetase, mutations in CLPP expose dysfunction of mitochondrial protein homeostasis as a cause of Perrault syndrome.


Diabetes | 2013

Insights Into the Molecular Mechanism for Type 2 Diabetes Susceptibility at the KCNQ1 Locus From Temporal Changes in Imprinting Status in Human Islets

Mary E. Travers; Deborah J.G. Mackay; Marloes Dekker Nitert; Andrew P. Morris; Cecilia M. Lindgren; Andrew Berry; Paul Johnson; Neil A. Hanley; Leif Groop; Mark I. McCarthy; Anna L. Gloyn

The molecular basis of type 2 diabetes predisposition at most established susceptibility loci remains poorly understood. KCNQ1 maps within the 11p15.5 imprinted domain, a region with an established role in congenital growth phenotypes. Variants intronic to KCNQ1 influence diabetes susceptibility when maternally inherited. By use of quantitative PCR and pyrosequencing of human adult islet and fetal pancreas samples, we investigated the imprinting status of regional transcripts and aimed to determine whether type 2 diabetes risk alleles influence regional DNA methylation and gene expression. The results demonstrate that gene expression patterns differ by developmental stage. CDKN1C showed monoallelic expression in both adult and fetal tissue, whereas PHLDA2, SLC22A18, and SLC22A18AS were biallelically expressed in both tissues. Temporal changes in imprinting were observed for KCNQ1 and KCNQ1OT1, with monoallelic expression in fetal tissues and biallelic expression in adult samples. Genotype at the type 2 diabetes risk variant rs2237895 influenced methylation levels of regulatory sequence in fetal pancreas but without demonstrable effects on gene expression. We demonstrate that CDKN1C, KCNQ1, and KCNQ1OT1 are most likely to mediate diabetes susceptibility at the KCNQ1 locus and identify temporal differences in imprinting status and methylation effects, suggesting that diabetes risk effects may be mediated in early development.


The FASEB Journal | 2007

Use of gene expression profiling to identify a novel glucocorticoid sensitivity determining gene, BMPRII

Rachelle Donn; Andrew Berry; Adam Stevens; Stuart N. Farrow; Joanna Betts; Richard Stevens; Chris Clayton; Jixian Wang; Linda Warnock; Jane Worthington; Laurie Scott; Simon J Graham; David Ray

Wide variation in glucocorticoid (Gc) sensitivity exists between individuals which may influence susceptibility to, and treatment response of, inflammatory diseases. To determine a genetic fingerprint of Gc sensitivity 100 healthy human volunteers were polarized into the 10% most Gc‐sensitive and 10% most Gc‐resistant following a low dose dexamethasone (0.25mg) suppression test. Gene expression profiling of primary lymphocytes identified the 98 most significantly Gc regulated genes. These genes were used to build a subnetwork of Gc signaling, with 54 genes mapping as nodes, and 6 non‐Gc regulated genes inferred as signaling nodes. Twenty four of the 98 genes showed a difference in Gc response in vitro dependent on the Gc sensitivity of their donor individuals in vivo. A predictive model was built using both partial least squares discriminate analysis and support vector machines that predicted donor glucocorticoid sensitivity with 87% accuracy. Discriminating genes included bone morphogenetic protein receptor, type II (BMPRII). Transfection studies showed that BMPRII modulated Gc action. These studies reveal a broad base of gene expression that predicts Gc sensitivity and determine a Gc signaling network in human primary T lymphocytes. Furthermore, this combined gene profiling, and functional analysis approach has identified BMPRII as a modulator of Gc signaling.—Donn, R., Berry, A., Stevens, A., Farrow, S., Betts, J., Stevens, R., Clayton, C., Wang, J., Warnock, L., Worthington, J., Scott, L., Graham, S., Ray, D. Use of gene expression profiling to identify a novel glucocorticoid sensitivity determining gene, BMPRII. FASEB J. 21, 402–414 (2007)


Nature Cell Biology | 2015

TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors

Inês Cebola; Santiago A. Rodríguez-Seguí; Candy H.-H. Cho; José Bessa; Meritxell Rovira; Mario Luengo; Mariya Chhatriwala; Andrew Berry; Joan Ponsa-Cobas; Miguel Angel Maestro; Rachel Jennings; Lorenzo Pasquali; Ignasi Moran; Natalia Castro; Neil A. Hanley; José Luis Gómez-Skarmeta; Ludovic Vallier; Jorge Ferrer

The genomic regulatory programmes that underlie human organogenesis are poorly understood. Pancreas development, in particular, has pivotal implications for pancreatic regeneration, cancer and diabetes. We have now characterized the regulatory landscape of embryonic multipotent progenitor cells that give rise to all pancreatic epithelial lineages. Using human embryonic pancreas and embryonic-stem-cell-derived progenitors we identify stage-specific transcripts and associated enhancers, many of which are co-occupied by transcription factors that are essential for pancreas development. We further show that TEAD1, a Hippo signalling effector, is an integral component of the transcription factor combinatorial code of pancreatic progenitor enhancers. TEAD and its coactivator YAP activate key pancreatic signalling mediators and transcription factors, and regulate the expansion of pancreatic progenitors. This work therefore uncovers a central role for TEAD and YAP as signal-responsive regulators of multipotent pancreatic progenitors, and provides a resource for the study of embryonic development of the human pancreas.


Development | 2015

Human pancreas development

Rachel Jennings; Andrew Berry; James Strutt; David T. Gerrard; Neil A. Hanley

A wealth of data and comprehensive reviews exist on pancreas development in mammals, primarily mice, and other vertebrates. By contrast, human pancreatic development has been less comprehensively reviewed. Here, we draw together those studies conducted directly in human embryonic and fetal tissue to provide an overview of what is known about human pancreatic development. We discuss the relevance of this work to manufacturing insulin-secreting β-cells from pluripotent stem cells and to different aspects of diabetes, especially permanent neonatal diabetes, and its underlying causes. Summary: This Review presents a human-centric view of the latest advances in our understanding of pancreas development and the relevance of these insights from a clinical perspective.

Collaboration


Dive into the Andrew Berry's collaboration.

Top Co-Authors

Avatar

Neil A. Hanley

University of Manchester

View shared research outputs
Top Co-Authors

Avatar

David Ray

University of Manchester

View shared research outputs
Top Co-Authors

Avatar

Karen Hanley

University of Manchester

View shared research outputs
Top Co-Authors

Avatar

Laura Matthews

University of Manchester

View shared research outputs
Top Co-Authors

Avatar

Rachel Jennings

Central Manchester University Hospitals NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Rachelle Donn

University of Manchester

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Adam Stevens

University of Manchester

View shared research outputs
Top Co-Authors

Avatar

Anne White

University of Manchester

View shared research outputs
Top Co-Authors

Avatar

Anthony D. Whetton

Manchester Academic Health Science Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge